Appeal No. 2005-1511
Application No. 09/879,398
Lamb et al. (Lamb), “Increased frequency of TCR γδ+ T cells in disease-
free survivors following T cell-depleted, partially mismatched, related
donor bone marrow transplantation for leukemia,” J. Hematotherapy, Vol.
5, pp. 503-509 (1996).
Coligan et al. (Coligan), Current Protocols in Immunology, Vol. 2, Chapter
7.4, pp. 7.4.1-7.4.6, John Wiley & Sons, Inc. (1995).
Falkenburg et al. (Falkenburg), “Generation of donor-derived antileukemic
cytotoxic T-lymphocyte responses for treatment of relapsed leukemia after
allogeneic HLA-identical bone marrow transplantation.” J. Immunotherapy,
Vol. 14, pp. 305-309 (1993).
Viale et al. (Viale), “TCR γ/δ positive lymphocytes after allogeneic bone
marrow transplantation,” Bone Marrow Transplantation, Vol. 10, pp. 249-
253 (1992).
Duval et al. (Duval), “Potential antileukemic effect of γδ T cells in acute
lymphoblastic leukemia,” Leukemia, Vol. 9, pp. 863-868 (1995).
Bigby et al. (Bigby), “Most γδ T cells develop normally in the absence of
MHC class II molecules,” J. of Immunology, Vol. 151, pp. 4465-75 (1993).
Skyes et al. (Skyes), “Interleukin 2 prevents graft-versus-host disease
while preserving the graft-versus-leukemia effect of allogeneic T cells,”
Proc. Natl. Acad. Sci., USA, Vol. 87, pp. 5633-37 (1990).
The claims stand rejected as follows:
I. Claims 2, 3, 6, 7, 12, 16 and 18 stand rejected under 35 U.S.C. § 103(a) as
being unpatentable over Bell, Ensslin, Lamb, Coligan and Falkenburg.
II. Claims 4 and 5 stand rejected under 35 U.S.C. § 103(a) as being
unpatentable over Bell, Ensslin, Lamb, Coligan and Falkenburg as applied to
claims 2, 3, 6, 7, 12, 16 and 18, above, and in further view of Viale and Duval.
III. Claim 11 stands rejected under 35 U.S.C. § 103(a) as being unpatentable
over Bell, Ensslin, Lamb, Coligan and Falkenburg as applied to claims 2, 3, 6, 7,
12, 16 and 18, above, and in further view of Bigby and Sykes.
3
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Next
Last modified: November 3, 2007